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moxazole and Ciproﬂoxacin. AMR surveillance revealed that
the prevalence of multi-drug resistant (MDR) Salmonella
(resistant to three or more at a time) has been decreas-
ing gradually (30% in 2002, 13%in 2003, 5% in 2004 and 2%
each in 2005 and 2006) in Nepal.
Conclusions: Although the number of MDR Salmonella has
been decreasing in Nepal, the total number of Salmonella
isolates has been increasing. The increasing trend of S.
paratyphi A with high resistance rate of Nalidixic acid can be
regarded as a worrisome situation and may reﬂect the emer-
gence of ﬂuoroquinolone resistance. Continued surveillance
and inclusion of appropriate antimicrobials in the routine
susceptibility testing for Salmonella are necessary in Nepal.
doi:10.1016/j.ijid.2008.05.1091
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Background: The hepatitis B virus (HBV) is an enveloped
DNA virus with an icosahedral capsid replicating via reverse
transcription. The crystal structure of the capsid is known.
The viral envelope contains three different coterminal pro-
teins (S, M, and L proteins) spanning the membrane several
times. Hepatitis B virus large surface protein ‘LHBs’ has
the unusual property of accumulating in a particulate form
within a preGolgi compartment, leading to marked prolifer-
ation of intracellular membranes
Objective: The aim of this study was to investigate the
clinical value of LHBs used for diagnosis of the clinical hep-
atitis B patient and relativity with replication of hepatitis B
virus.
Methods: A total of 600 HBsAg positive patients in
The Fourth people’s hospital of Shenzhen between April-
December 2006 were included to the study. The patients
were classiﬁed into two groups according to their serologi-
cal patterns (Group 1: HBeAg positive 300 cases; Group 2:
HBeAg negative 300 cases). The age and gender distribu-
tions of the groups were similar. HBV serological markers and
LHBs have been detected by Enzyme Linked Immunosorbent
Assay (ELISA), and viral load (HBV-DNA) were investigated
by real-time polymerase chain reaction(PCR)
Results: No signiﬁcant difference of positive rate was
observed between HBV DNA 76.17% (457/600) and LHBs
77.33% (464/600) (X2 = 0.696, P > 0.05) in 600 HBsAg-positive
serum samples; Postive rate of HBV DNA and LHBs were 95.0
(285/300) and 96.0 (288/300) in HBeAg postive samples and
were 57.33 (172/300) and 58.67 (176/300) in HBeAg neg-
ative samples(X20.725, P > 0.05; X20.253, P > 0.05); Serum
LHBs levels were correlated with the serum HBV DNA copies
(r = 0.948).
Conclusion: The results demonstrated that there is a per-
fect correlation between the copies of HBV-DNA and the
levels of LHBs, and LHBs expression can reﬂect the repli-
cation of HBV.
doi:10.1016/j.ijid.2008.05.1092
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Objective: The persistence of Anti-HBc IgM among inac-
tive HBsAg carriers may be with hidden dangers anf forecasts
the existence of liver damage. A trial of lamivudine in such
carriers was carried out for the ﬁrst time in this study.
Patients and Methods: A total of 62 Inactive HBsAg carri-
ers (age range; 25—45 years) with persistence of anti-HBc
IgM were randomized to receive either 100mg lamivu-
dine (32/62) or placebo (30/60) daily for 6 months. The
studied carriers were regular attendees of the Virology
Center in Mosul, North Iraq for follow-up. Enzyme-linked
immunosorbent assay techniques were performed to detect
the different markers of HBV infection
Results: Among the lamivudine group, anti-HBc IgM serol-
clearance rate was 81.3% and HBsAg seroconversion rate was
9.4% compared to 6.3% and 3.3% among placebo group. Num-
ber of adverse clinical events were observed, but were of
mild nature and tolerable by the participants who completed
the study
Conclusions: The trial of lamivudine in this group of
inactive HBsAg carrier state cases proved to be safe and
efﬁcacious.
doi:10.1016/j.ijid.2008.05.1093
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Background: HCV infection is very common in intra-
venous drug usres (IDUs) and it has more often progression
in chronic hepatitis. Inspite of that, just small percent of
these patients with chronic hepatitis C (CHC) is treated with
antiviral therapy. Interruption of therapy was common in
IDUs due to low compliance and adverse reactions, usually
psychiatric.
Methods: This is a 5-year retrospective analysis of 37 IDUs
with CHC who were treated in Institute for Infectious and
Tropical Diseases, Clinical Center of Serbia in Belgrade. HCV
RNA and HCV genotype (G) were determinated by PCR. Liver
biopsy was performed in 34 (91,89%) patients. All 37 patients
were treated with pegilated interferon alpha 2a+ Ribavirin
according to standard protocols
Results: There were 37 IDUs with CHC in the age from
17—54 years. They abused heroin iv for 1—21 years. HCV
infection was diagnosed 1—18 years before treatment. All
patients were HBsAg and anti-HIV negative. 18 patients
(48,64%) also consumed alcohol. AST level ranged from
35—248 IU/L. Liver biopsy showed cirrhosis in 5 (14,7%)
patients and ﬁbrosis in 29 (85,3%) patients. Steatosis was
conﬁrmed in 9 (24,32%) patients. Viral load ranged from
